• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    65 Biggest Movers From Yesterday

    12/21/21 5:25:51 AM ET
    $AERC
    $AMTX
    $APTS
    $ARDS
    Environmental Services
    Utilities
    Major Chemicals
    Industrials
    Get the next $AERC alert in real time by email

    Gainers

    • Society Pass Incorporated (NASDAQ:SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index.
    • Bluerock Residential Growth REIT, Inc. (NYSE:BRG) surged 76.2% to close at $27.20. Blackstone agreed to buy Bluerock Residential Growth REIT in a deal valued at $3.6 billion, extending its push into U.S. rental housing.
    • Can-Fite BioPharma Ltd. (NYSE:CANF) rose 69.3% to settle at $2.15 after the company announced a liver cancer patient was cleared of all cancer lesions.
    • Verso Corporation (NYSE:VRS) shares jumped 34.9% to close at $27.04 after the company announced it would be acquired by BillerundKorsnas for $27 per share.
    • AeroClean Technologies, Inc. (NASDAQ:AERC) gained 33.7% to settle at $11.31.
    • AeroClean Technologies recently announced plans to install Pūrgo devices at MADabolic Jupiter.
    • Cue Health Inc. (NASDAQ:HLTH) jumped 28.9% to settle at $12.63. Cue Health recently appointed Nitin Duggal as its first Chief Marketing Officer.
    • Galera Therapeutics, Inc. (NASDAQ:GRTX) rose 28% to settle at $3.79. Citigroup maintained Galera Therapeutics with a Buy and raised the price target from $11 to $20.
    • BioDelivery Sciences International, Inc. (NASDAQ:BDSI) gained 26.9% to close at $3.30. BioDelivery Sciences said the US District Court issued opinion in favor of the company in patent litigation against Alvogen.
    • Roivant Sciences Ltd. (NASDAQ:ROIV) climbed 23.5% to settle at $13.52 after gaining 18% on Friday.
    • Lucira Health, Inc. (NASDAQ:LHDX) gained 22.9% to close at $6.70.
    • HeartBeam, Inc. (NASDAQ:BEAT) jumped 21.5% to settle at $3.56. Benchmark initiated coverage on BioTelemetry with a Speculative Buy rating and announced a price target of $9.
    • Lineage Cell Therapeutics, Inc. (NYSE:LCTX) gained 21.2% to close at $2.57. Lineage Cell Therapeutics entered into an exclusive worldwide collaboration and license agreement with Roche Holdings’ Genentech to develop and commercialize retinal pigment epithelium (RPE) cell therapy.
    • Innovid Corp. (NYSE:CTV) jumped 20.7% to settle at $8.15. Evercore ISI Group recently initiated coverage on Innovid with an Outperform rating and announced a price target of $10.
    • StarTek, Inc. (NYSE:SRT) climbed 20.6% to settle at $4.75.
    • The Oncology Institute, Inc. (NASDAQ:TOI) gained 19.6% to close at $7.63.
    • Quotient Limited (NASDAQ:QTNT) rose 19.5% to close at $2.70. Quotient recently won a $77 million Defense Logistics Agency contract.
    • Local Bounti Corporation (NYSE:LOCL) surged 19% to settle at $6.44.
    • Fortuna Silver Mines Inc. (NYSE:FSM) gained 17.7% to close at $3.79 after the company announced the SEMARNAT granted a twelve year extension of the environmental impact authorization at the San Jose Mine, located in Oaxaca, Mexico.
    • Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) surged 17.6% to settle at $2.54. Aridis Pharmaceuticals recently reported a Q3 loss of $1.94 per share.
    • New Pacific Metals Corp. (NYSE:NEWP) gained 17.6% to close at $3.01.
    • Talaris Therapeutics, Inc. (NASDAQ:TALS) jumped 17.3% to settle at $14.85 after the stock was added to the Nasdaq Biotechnology Index.
    • Energy Focus, Inc. (NASDAQ:EFOI) gained 16.9% to close at $3.88.
    • Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) rose 15.8% to close at $45.35 after the company's Caplyta was approved by the FDA for bipolar depression.
    • Preferred Apartment Communities, Inc. (NYSE:APTS) gained 15.2% to settle at $16.57.
    • Biomea Fusion, Inc. (NASDAQ:BMEA) surged 14.4% to close at $8.26. Oppenheimer recently initiated coverage on Biomea Fusion with an Outperform rating and announced a price target of $22.
    • Lottery.com Inc. (NASDAQ:LTRY) gained 14.1% to settle at $5.99.
    • Backblaze, Inc. (NASDAQ:BLZE) surged 13.6% to close at $19.49.
    • Backblaze recently posted a Q3 loss of $0.32 per share.
    • BP Midstream Partners LP (NYSE:BPMP) rose 13.3% to close at $14.63. BP announced agreement to acquire remaining stake in BP Midstream Partners, Reuters reported.
    • TeraWulf Inc. (NASDAQ:WULF) jumped 13.1% to settle at $14.65.
    • Limelight Networks, Inc. (NASDAQ:LLNW) jumped 12% to settle at $3.63. Raymond James upgraded Limelight Networks from Market Perform to Strong Buy.
    • Calliditas Therapeutics AB (NASDAQ:CALT) gained 11.9% to close at $26.26 after HC Wainwright & Co maintained a Buy rating on the stock and raised its price target from $52 to $62. Calliditas Therapeutics recently announced it was granted by the FDA accelerated approval of TARPEYO to reduce proteinuria in lgA nephropathy.
    • GBS Inc. (NASDAQ:GBS) climbed 11.1% to settle at $1.40 after dipping 23% on Friday. GBS recently announced application for FDA breakthrough device designation to fast track rapid saliva glucose test.
    • CIT Group Inc. (NYSE:CIT) gained 10% to close at $50.94. First Citizens recently announced receipt of regulatory approvals for deal with CIT.
    • argenx SE (NASDAQ:ARGX) jumped 9% to settle at $337.51 after the company announced the FDA approved VYVGART for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive.
    • KemPharm, Inc. (NASDAQ:KMPH) gained 6.8% to close at $8.31 as the company reported authorization of $50 million buyback.

     

    Check out these big penny stock gainers and losers

    Losers

    • Summit Therapeutics Inc. (NASDAQ:SMMT) shares tumbled 48% to close at $2.59 on Monday after reporting topline results for Phase III Ri-CoDIFy study for C. Difficile infection. The company said Ri-CoDIFy did not meet primary endpoint.
    • Insignia Systems, Inc. (NASDAQ:ISIG) dropped 35.1% to settle at $11.50.
    • Nutriband Inc. (NASDAQ:NTRB) fell 23.6% to settle at $3.14.
    • Optical Cable Corporation (NASDAQ:OCC) fell 21% to close at $5.09 after the company reported Q4 earnings results.
    • PARTS iD, Inc. (NYSE:ID) fell 19.2% to settle at $2.15.
    • Immix Biopharma, Inc. (NASDAQ:IMMX) declined 18.8% to close at $3.25 amid post-IPO volatility.
    • Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) dropped 18.5% to close at $2.60. Bellerophon Therapeutics jumped around 35% on Friday after topline data from Phase 2 study (PULSE-PHPF-002) evaluating the acute hemodynamic benefit of INOpulse via right heart catheterization for pulmonary hypertension associated with sarcoidosis (PH-Sarc).
    • Vera Therapeutics, Inc. (NASDAQ:VERA) dropped 18.1% to close at $20.27. Vera Therapeutics recently reported the purchase of monoclonal antibody from Pfizer.
    • Aemetis, Inc. (NASDAQ:AMTX) declined 18.1% to settle at $12.21.
    • Tuya Inc. (NYSE:TUYA) fell 17.8% to close at $5.37.
    • Blue Star Foods Corp. (NASDAQ:BSFC) shares dropped 17.7% to settle at $2.05. Blue Star Foods recently announced plans to acquire the assets of Gault Seafood, LLC.
    • CNFinance Holdings Limited (NYSE:CNF) shares declined 16.1% to close at $3.86.
    • Mawson Infrastructure Group, Inc. (NASDAQ:MIGI) dropped 15.9% to settle at $7.26.
    • Rubius Therapeutics, Inc. (NASDAQ:RUBY) fell 15.5% to settle at $10.63.
    • Sociedad Química y Minera de Chile S.A. (NYSE:SQM) dropped 15.3% to close at $47.38.
    • Vicarious Surgical Inc. (NYSE:RBOT) shares declined 15.2% to settle at $9.97.
    • Spruce Biosciences, Inc. (NASDAQ:SPRB) fell 15.1% to close at $4.27. Spruce Biosciences shares jumped more than 102% on Friday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $15 price target.
    • Cassava Sciences, Inc. (NASDAQ:SAVA) dropped 15% to settle at $36.77.
    • Humanigen, Inc. (NASDAQ:HGEN) fell 15% to close at $3.75.
    • Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT) fell 14.9% to close at $3.14.
    • Nuvalent, Inc. (NASDAQ:NUVL) fell 14.5% to close at $19.54.
    • ForgeRock, Inc. (NYSE:FORG) fell 14.1% to close at $21.71. The company recently disclosed two significant new features to the ForgeRock Identity Cloud called Organizations and Themed User Journeys.
    • Stronghold Digital Mining, Inc. (NASDAQ:SDIG) fell 13.7% to close at $10.87. Stronghold Digital Mining said it acquired 9,080 bitcoin miners and secured $54 million equipment financing.
    • Regis Corporation (NYSE:RGS) dropped 12.6% to settle at $2.08.
    • Argo Blockchain plc (NASDAQ:ARBK) fell 12.3% to close at $11.38 after rising around 5% on Friday.
    • Ipsidy Inc. (NASDAQ:AUID) fell 10.8% to close at $14.92.
    • Sono Group N.V. (NASDAQ:SEV) declined 10.8% to close at $10.13.
    • Zhihu Inc. (NYSE:ZH) shares fell 9.6% to close at $5.17. China summoned Zhihu for unlawful release of information.
    • California Resources Corporation (NYSE:CRC) fell 9% to close at $38.63.
    • Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) shares fell 8.4% to close at $0.6764. Eloxx Pharmaceuticals shares climbed 12% on Friday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $4 price target.
    Get the next $AERC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AERC
    $AMTX
    $APTS
    $ARDS

    CompanyDatePrice TargetRatingAnalyst
    Sociedad Quimica y Minera S.A.
    $SQM
    1/22/2026$90.00Buy → Neutral
    Clarksons Platou
    Biomea Fusion Inc.
    $BMEA
    1/13/2026$8.00Buy
    Rodman & Renshaw
    Sociedad Quimica y Minera S.A.
    $SQM
    1/13/2026$88.00Hold → Buy
    Deutsche Bank
    California Resources Corporation
    $CRC
    1/9/2026Outperform → Neutral
    Pickering Energy Partners
    TeraWulf Inc.
    $WULF
    12/31/2025$24.00Mkt Perform → Outperform
    Keefe Bruyette
    Spruce Biosciences Inc.
    $SPRB
    12/23/2025$283.00Outperform
    Oppenheimer
    argenx SE
    $ARGX
    12/18/2025$858.00Outperform → Neutral
    Robert W. Baird
    Summit Therapeutics Inc.
    $SMMT
    12/17/2025$18.00Underweight → Equal Weight
    Barclays
    More analyst ratings

    $AERC
    $AMTX
    $APTS
    $ARDS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BRISBANE, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on February 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 11,500 shares of Class A common stock and restricted stock units (RSUs) underlying 5,750 shares of Class A common stock to two (2) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stoc

    2/6/26 4:05:00 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TeraWulf Schedules Conference Call for Fourth Quarter 2025 Financial Results

    EASTON, Md., Feb. 06, 2026 (GLOBE NEWSWIRE) -- TeraWulf Inc. (NASDAQ:WULF) ("TeraWulf" or the "Company"), a leading owner and operator of vertically integrated digital infrastructure, today announced that it will host its earnings conference call and webcast for the fourth quarter ended December 31, 2025 on Thursday, February 26, 2026 at 4:30 p.m. Eastern Time. A press release detailing the Company's financial results will be issued prior to the call on the same day. Conference Call Information To participate in this event, please log on or dial in approximately five minutes before the scheduled start time. Date: February 26, 2026Time: 4:30 p.m. ETAccess ID: 13758665Webcast: https://vi

    2/6/26 9:28:54 AM ET
    $WULF
    EDP Services
    Technology

    Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025

    Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 P<0.0001). Brepocitinib demonstrated rapid, deep and sustained improvements across all other efficacy endpoints measured with consistent safety profilePriovant plans to progress CS to a pivotal program with a Phase 3 study starting in calendar year 2026 following engagement with the FDA, representing the third indication with a pivotal program for brepocitinib New Drug Application (NDA) was submitted to the FDA for brepocitinib in dermatomyositis (DM). Topline data from Phase 3 studies in non-infectiou

    2/6/26 7:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AERC
    $AMTX
    $APTS
    $ARDS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    FDA Approval for TARPEYO issued to CALLIDITAS THERAPEUTICS AB

    Submission status for CALLIDITAS THERAPEUTICS AB's drug TARPEYO (ORIG-1) with active ingredient BUDESONIDE has changed to 'Approval' on 12/15/2021. Application Category: NDA, Application Number: 215935, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/20/21 3:40:41 PM ET
    $CALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AERC
    $AMTX
    $APTS
    $ARDS
    SEC Filings

    View All

    Amendment: SEC Form S-1/A filed by Society Pass Incorporated

    S-1/A - SOCIETY PASS INCORPORATED. (0001817511) (Filer)

    2/6/26 5:26:07 PM ET
    $SOPA
    Real Estate

    Society Pass Incorporated filed SEC Form 8-K: Other Events

    8-K - SOCIETY PASS INCORPORATED. (0001817511) (Filer)

    2/6/26 5:00:27 PM ET
    $SOPA
    Real Estate

    Aemetis Inc. (DE) filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - AEMETIS, INC (0000738214) (Filer)

    2/6/26 4:51:52 PM ET
    $AMTX
    Major Chemicals
    Industrials

    $AERC
    $AMTX
    $APTS
    $ARDS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Endeavor Blockchain, Llc bought $192,502 worth of shares (42,100 units at $4.57), decreasing direct ownership by 100% to 4,397 units (SEC Form 4)

    4 - Mawson Infrastructure Group Inc. (0001218683) (Issuer)

    1/30/26 7:58:02 PM ET
    $MIGI
    Finance: Consumer Services
    Finance

    Large owner Endeavor Blockchain, Llc bought $290,400 worth of shares (60,000 units at $4.84), increasing direct ownership by 4% to 1,460,000 units (SEC Form 4)

    4 - Mawson Infrastructure Group Inc. (0001218683) (Issuer)

    1/26/26 7:22:56 PM ET
    $MIGI
    Finance: Consumer Services
    Finance

    Large owner Endeavor Blockchain, Llc bought $4,388,681 worth of shares (801,279 units at $5.48) (SEC Form 4)

    4 - Mawson Infrastructure Group Inc. (0001218683) (Issuer)

    1/22/26 5:47:16 PM ET
    $MIGI
    Finance: Consumer Services
    Finance

    $AERC
    $AMTX
    $APTS
    $ARDS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sociedad Quimica y Minera downgraded by Clarksons Platou with a new price target

    Clarksons Platou downgraded Sociedad Quimica y Minera from Buy to Neutral and set a new price target of $90.00

    1/22/26 8:26:36 AM ET
    $SQM
    Mining & Quarrying of Nonmetallic Minerals (No Fuels)
    Industrials

    Rodman & Renshaw initiated coverage on Biomea Fusion with a new price target

    Rodman & Renshaw initiated coverage of Biomea Fusion with a rating of Buy and set a new price target of $8.00

    1/13/26 10:18:10 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sociedad Quimica y Minera upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Sociedad Quimica y Minera from Hold to Buy and set a new price target of $88.00

    1/13/26 8:44:16 AM ET
    $SQM
    Mining & Quarrying of Nonmetallic Minerals (No Fuels)
    Industrials

    $AERC
    $AMTX
    $APTS
    $ARDS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Grant Sean was granted 25,000 shares, increasing direct ownership by 27% to 119,130 units (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    2/6/26 8:00:13 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, FINANCE, CHIEF ACCT OFFCR Young Joseph R was granted 10,000 shares, increasing direct ownership by 17% to 67,839 units (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    2/6/26 8:00:16 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Skelton Laurence Matthew was granted 20,000 shares, increasing direct ownership by 44% to 65,800 units (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    2/6/26 8:00:11 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AERC
    $AMTX
    $APTS
    $ARDS
    Leadership Updates

    Live Leadership Updates

    View All

    Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

    BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately. Mr. Skelton joined Vera Therapeutics over a year ago as the Executive Vice President, Commercial. "We are pleased to welcome Matt to the executive team as we prepare for the potential commercial launch of atacicept for the treatment of IgA nephropathy," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "With his track record

    1/28/26 7:30:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer

    Brings more than 25 years of experience in building and scaling groundbreaking cardiovascular technologies Will initially focus on launching the Company's FDA-cleared 12-lead ECG system for arrhythmia assessment Will lead the Company's broader commercialization strategy across key growth initiatives, including heart attack detection and the 12-lead ECG extended-wear patch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the appointment of Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. In this newly created role, Mr. Humbarger will lead commercial strate

    1/22/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Aptera Motors Appoints Automotive Industry Veteran Tony Kirton as Chairman of the Board of Directors

    CARLSBAD, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Aptera Motors Corp. (NASDAQ:SEV), a solar mobility company advancing ultra-efficient transportation, today announced that Tony Kirton has been appointed Chairman of the Board of Directors. Kirton brings more than four decades of global automotive leadership experience, having held senior executive and board roles across leading automotive brands including Volkswagen, Audi, and BMW. His appointment follows his service as an independent board director and supports Aptera's focus on disciplined governance and long-term value creation as the company prepares for production. "Over my career, I've seen many technologies promise transformation

    1/8/26 4:49:26 PM ET
    $SEV
    Auto Manufacturing
    Industrials

    $AERC
    $AMTX
    $APTS
    $ARDS
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Immix Biopharma Inc. on Jun 5

    Recent insider purchases at Immix Biopharma Inc. have caught the attention of investors, with Morris Gabriel S leading the way by acquiring $5,973 worth of shares on June 5, 2024. This transaction involved 3,300 units at a price of $1.81 per share, increasing Gabriel's direct ownership by 1% to 283,334 units, as reported in SEC Form 4. This move indicates Gabriel's confidence in the company's potential and may be seen as a positive signal by market participants. Click here for more details. Looking back at previous insider transactions, we can identify a few interesting patterns. On May 15, 2024, Rachman Ilya M purchased $9,660 worth of shares, comprising 4,300 units at $2.25 per share, whi

    6/10/24 1:09:24 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AERC
    $AMTX
    $APTS
    $ARDS
    Financials

    Live finance-specific insights

    View All

    TeraWulf Schedules Conference Call for Fourth Quarter 2025 Financial Results

    EASTON, Md., Feb. 06, 2026 (GLOBE NEWSWIRE) -- TeraWulf Inc. (NASDAQ:WULF) ("TeraWulf" or the "Company"), a leading owner and operator of vertically integrated digital infrastructure, today announced that it will host its earnings conference call and webcast for the fourth quarter ended December 31, 2025 on Thursday, February 26, 2026 at 4:30 p.m. Eastern Time. A press release detailing the Company's financial results will be issued prior to the call on the same day. Conference Call Information To participate in this event, please log on or dial in approximately five minutes before the scheduled start time. Date: February 26, 2026Time: 4:30 p.m. ETAccess ID: 13758665Webcast: https://vi

    2/6/26 9:28:54 AM ET
    $WULF
    EDP Services
    Technology

    Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025

    Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 P<0.0001). Brepocitinib demonstrated rapid, deep and sustained improvements across all other efficacy endpoints measured with consistent safety profilePriovant plans to progress CS to a pivotal program with a Phase 3 study starting in calendar year 2026 following engagement with the FDA, representing the third indication with a pivotal program for brepocitinib New Drug Application (NDA) was submitted to the FDA for brepocitinib in dermatomyositis (DM). Topline data from Phase 3 studies in non-infectiou

    2/6/26 7:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regis Corporation Reports Financial Results for the Second Fiscal Quarter 2026

    Transformation Efforts Gain Traction Across Supercuts and Corporate Networks Q2 Same-Store Sales for Supercuts Up 2.0%, Company-Owned Salons up 4.3%, Regis Consolidated Slightly Lower as Expected Due to Franchise Mix Loyalty Membership Enrollment Grows Steadily Regis Corporation (NASDAQGM:RGS), a leader in the haircare industry, today announced financial results for the second fiscal quarter ended December 31, 2025. Jim Lain, Regis Corporation's Interim President and Chief Executive Officer, commented, "Our second quarter results demonstrate improved execution and continued momentum, with same-store sales increasing 2.0% at Supercuts and 4.3% at company-owned salons. We delivered ye

    2/5/26 6:30:00 AM ET
    $RGS
    Other Consumer Services
    Consumer Discretionary

    $AERC
    $AMTX
    $APTS
    $ARDS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lineage Cell Therapeutics Inc.

    SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)

    11/21/24 8:05:56 PM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Blue Star Foods Corp.

    SC 13G/A - Blue Star Foods Corp. (0001730773) (Subject)

    11/14/24 7:34:10 PM ET
    $BSFC

    Amendment: SEC Form SC 13G/A filed by Spruce Biosciences Inc.

    SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)

    11/14/24 5:45:17 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care